John Chang, Simona Degli Esposti, Michael Karampelas, Giancarlo Sborgia, Bishwanath Pal, Adnan Tufail
To report the use of intravitreal anti-VEGF injections for treatment of choroidal neovascular membrane (CNV) secondary to punctate inner cho-roidopathy (PIC).
Retrospective case series of patients with active CNV secondary to PIC in a single tertiary centre that were treated with intravitreal bevacizumab and had at least 6 months of follow-up.
Data on 24 eyes of 23 patients meeting study inclusion criteria are presented. Mean age at diagnosis of CNV was 39 years. Mean VA at diagnosis of CNV was 68 ETDRS letters. 92% of eyes had intraretinal fluid (IRF) and 67% had subretinal fluid (SRF) on initial OCT. At 4–6 weeks after the first injection, mean VA improved to 76 ETDRS letters (p < 0.05) and 92% of eyes had either resolution or reduction of IRF and/or SRF on OCT. Mean follow-up was 26.7 months. Anti-VEGF treatment was given on a PRN basis, and the mean number of injections required over follow-up was 4.1 (range 1–9). Recurrence of CNV activity requiring recommencement of anti-VEGF treatment occurred in 9 eyes of 9 patients. Mean time to recur-rence was 8.8 months of injection-free period. Mean VA at final follow-up was 73 letters. Conclusion: This is the largest case series and with the longest follow-up of CNV secondary to PIC treated with anti-VEGF injections. Our findings demonstrate that this treatment is highly effective in treating active CNV in PIC with relatively few injections on a PRN basis. However, close follow-up is required due to high rates of recurrences requiring repeat injections.